Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Parkinsons Disease Therapeutics Market to 2019 - Pipeline Shows Shift towards Long Term Disease Management

Published: Dec-2013 | Format: PDF | GBI Research | Code: MRS - 1329

GBI Research has released the pharma report - “Parkinson’s Disease Therapeutics Market to 2019 - Pipeline Shows Shift towards Long Term Disease Management”. The Parkinson’s Disease (PD) market is dominated by symptomatic treatments targeting functional impairment in PD. Levodopa has remained the gold standard treatment for almost 40 years and has significantly improved patient quality of life. There is currently there is a huge unmet need for disease-modifying treatments that slow progression or have neuroprotective properties. Over the 2012–2019 forecast period, the PD market is anticipated to decline from $3.4 billion in 2012 to $2.9 billion in 2019, as a consequence of upcoming patent expirations of high-profile products such as Azilect, Stalevo and Comtan. Although a few market entrants are anticipated to enter the market over the forecast period, they are not expected to offset the impact of generic erosion. Despite their superior profiles over existing treatments, these new products are not expected to command a premium price as they will be competing against generic products. The current PD pipeline reflects a shift of focus to long-term PD management, marked by the development of key pipeline candidates targeting levodopa-associated motor complications. These products will have the potential to change the future treatment algorithm as side effects of dopaminergic therapies become more manageable.

Scope

  • A brief introduction to PD, including pathogenesis, disease staging, diagnosis and treatment algorithms
  • In-depth analysis of the drugs available for the treatment of PD, covering their safety, efficacy, treatment patterns, and strengths/weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy
  • Comprehensive review of the pipeline for PD therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period, on the basis of phase distribution, molecule type and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by Phase, molecule type, trial size, trial duration, and program failure rate analyses for each molecule type and mechanism of action
  • Multi-scenario market forecast data to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain
  • Discussion of the drivers of and barriers to market growth
  • Discussion of the licensing and co-development deals landscape in PD, by stage of development, molecule type and mechanism of action, as well as analysis both licensing and co-development deals by year, and network maps of licensing and co-development deals


Reasons to Buy

  • Understand the different levels of PD therapy from early-stage to advanced
  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
  • Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for PD therapeutics
  • Observe the trends in clinical trial duration and size amongst clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for PD therapeutics
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the PD therapeutics market
Table of Contents

1 Table of Contents 1
1.1 List of Tables 3
1.2 List of Figures 4

2 Executive Summary 5
2.1 Impact of Patent Expiration Unlikely to Be Diminished by New Market Entrants 5
2.2 Shifting Focus of Pipeline to Long-Term Management of Parkinson’s Disease 5
2.3 High Number of Neuroprotective Targets in Early Pipeline 5

3 Introduction 6
3.1 Overview 6
3.2 Epidemiology 6
3.3 Etiology 7
3.3.1 Loss of Dopaminergic Neurons 7
3.3.2 Genetic Factors 7
3.3.3 Exposure to Environmental Toxins 7
3.4 Pathophysiology 8
3.4.1 Pathophysiological Changes in Basal Ganglia in Parkinson’s Disease 10
3.4.2 Pathophysiological Changes Involved in the Rise of Motor Complications in Parkinson’s Disease 10
3.5 Symptoms 11
3.6 Co-morbidities and Complications 12
3.7 Diagnosis 12
3.7.1 Classification 13
3.8 Prognosis and Disease Staging 16
3.9 Treatment Options 17
3.9.1 Pharmacological Treatment 17
3.9.2 Non-pharmacological Treatments 19
3.9.3 Treatment Algorithm 20
3.10 GBI Research Report Guidance 24

4 Marketed Products 25
4.1 Therapeutic Landscape 26
4.1.1 Dopamine Replacement Therapies 26
4.1.2 MAO-B inhibitors 30
4.1.3 Dopamine Agonists 32
4.1.4 COMT Inhibitors 42
4.1.5 Nouriast (istradefylline) – Kyowa Hakko Kirin 44
4.1.6 Exelon (rivastigmine tartrate) – Novartis AG 44
4.1.7 Symmetrel (amantadine hydrochloride) – Alliance Pharma Plc 46
4.1.8 Other drugs targeting non-motor symptoms of PD 47
4.2 Comparative Efficacy and Safety 48
4.3 Unmet Need 52

5 Pipeline for Parkinson’s Disease 53
5.1 Overall Pipeline 53
5.2 Molecular Targets in Parkinson’s Disease Pipeline 55
5.3 Clinical Trials 58
5.3.1 Failure Rate of Developmental Pipeline 58
5.3.2 Clinical Trial Sizes 61
5.3.3 Clinical Trial Duration 62
5.3.4 Summary of Clinical Trial Cost and Risk Analyses 64
5.4 Promising Candidates in Pipeline 65
5.4.1 Rytary (carbidopa, levodopa) – Impax Laboratories, Inc. 65
5.4.2 Safinamide – Newron Pharmaceuticals S.p.A 65
5.4.3 Pimavanserin – Acadia Pharmaceuticals Inc. 66
5.4.4 Tozadenant – Biotie Therapies 67
5.4.5 Mavoglurant – Novartis AG 67
5.4.6 Dipraglurant – Addex Therapeutics 68
5.5 Heat Map of Safety and Efficacy for Parkinson’s Disease Pipeline and Marketed Products 69

6 Market Forecast to 2019 73
6.1 Geographical Markets 73
6.1.1 Global Market 74
6.1.2 North America 76
6.1.3 Top Five Countries of Europe 79
6.1.4 Japan 82
6.2 Drivers and Barriers 85
6.2.1 Drivers 85
6.2.2 Barriers 86

7 Deals and Strategic Consolidations 88
7.1 Major Co-development Deals 88
7.1.1 Newron Pharmaceuticals S.p.A. Enter Agreement with Zambon Company S.p.A. 91
7.1.2 QR Pharma, Inc. Enter Research Agreement with Massachusetts General Hospital 91
7.1.3 Ceregene, Inc. Enter Agreement with Genzyme Corporation 91
7.2 Major Licensing Deals 91
7.2.1 Biotie Therapies Corp. Enter Worldwide Agreement with UCB Group 94
7.2.2 Ono Pharmaceutical Co., Ltd. Enter Agreement with Bial - Portela & Ca, S.A 94
7.2.3 Domain Therapeutics S.A. Enter Agreement with Prexton Therapeutics 95
7.2.4 Newron Pharmaceuticals S.p.A. Enter Agreement with Zambon Company S.p.A. 95
7.2.5 Oncodesign SA Enter Agreement with Ipsen S.A. 95
7.2.6 Cephalon, Inc. Enter Licensing Agreement with Mesoblast Limited 95
7.2.7 Shire Pharmaceutical Group Plc Enter Agreement with Heptares Therapeutics Ltd. 96

8 Appendix 97
8.1 All Pipeline Products, by Phase 97
8.2 Sources 114
8.3 Market Definition 123
8.4 Abbreviations 123
8.5 Research Methodology 125
8.5.1 Coverage 125
8.5.2 Secondary Research 125
8.6 Therapeutic Landscape 125
8.7 Epidemiology-Based Forecasting 126
8.8 Market Size by Geography 126
8.9 Geographical Landscape 127
8.10 Pipeline Analysis 127
8.11 Competitive Landscape 128
8.11.1 Expert Panel Validation 128
8.12 Contact Us 128
8.13 Disclaimer 128

List of Tables

Table 1: Definition of the Stages of Disability in Hoehn and Yahr Scale 13
Table 2: Evaluation of Disability by UPDRS 14
Table 3: Definition of the Stages of Disability in Hoehn and Yahr Scale 97
Table 4: Evaluation of Disability by UPDRS 97
Table 5: All Pipeline Products by Phase, Discovery 98
Table 6: All Pipeline Products by Phase, Preclinical 100
Table 7: All Pipeline Products by Phase, IND/CTA Filed and Phase I 107
Table 8: All Pipeline Products by Phase, Phase II 109
Table 9: All Pipeline Products by Phase, Phase III and Pre-registration 110
Table 10: Parkinson’s Disease, Global, Market Forecast, 2012-2019 111
Table 11: Parkinson’s Disease, US, Market Forecast, 2012-2019 111
Table 12: Parkinson’s Disease, Canada, Market Forecast, 2012-2019 111
Table 13: Parkinson’s Disease, UK, Market Forecast, 2012-2019 112
Table 14: Parkinson’s Disease, France, Market Forecast, 2012-2019 112
Table 15: Parkinson’s Disease, Germany, Market Forecast, 2012-2019 112
Table 16: Parkinson’s Disease, Italy, Market Forecast, 2012-201 113
Table 17: Parkinson’s Disease, Spain, Market Forecast, 2012-2019 113
Table 18: Parkinson’s Disease, Japan, Market Forecast, 2012-2019 113
List of Figures


Figure 1: Indirect and Direct Pathway in Basal Ganglia 9
Figure 2: Treatment Algorithm of Parkinson’s Disease 21
Figure 3: Treatment Algorithm of Advanced Parkinson’s Disease 22
Figure 4: Parkinson’s Disease Market, Global, Annual Sales of Madopar ($m), 2008–2012 27
Figure 5: Parkinson’s Disease Market, Global, Annual Sales of Stalevo and Comtan ($m), 2005–2012 28
Figure 6: Parkinson’s Disease Market, Global, Annual Sales of Azilect ($m), 2006–2012 31
Figure 7: Parkinson’s Disease Market, Global, Annual Sales of Requip ($m), 2001–2012 33
Figure 8: Parkinson’s Disease Market, Global, Annual Sales of Mirapex ($m), 2005–2010 35
Figure 9: Parkinson’s Disease Market, Global, Annual Sales of Neupro ($m), 2007–2012 37
Figure 10: Parkinson’s Disease Market, Global, Annual Sales of Apokyn ($m), 2006–2011 39
Figure 11: Parkinson’s Disease Market, Global, Annual Sales of Permax ($m), 2009–2012 40
Figure 12: Parkinson’s Disease Market, Global, Annual Sales of Exelon ($m), 2002–2012 45
Figure 13: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products, 2012–2019 49
Figure 14: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products, 2012–2019 50
Figure 15: Pipeline for Parkinson’s Disease, Global, 2012 54
Figure 16: Pipeline for Parkinson’s Disease, Global, 2012 55
Figure 17: Pipeline for Parkinson’s Disease, Global, Clinical Trial Failure Rates (%), 2006–2012 59
Figure 18: Pipeline for Parkinson’s Disease, Global, Clinical Trial Sizes (Participants), 2006–2012 61
Figure 19: Pipeline for Parkinson’s Disease, Global, Clinical Trial Duration (Months), 2006–2012 63
Figure 20: Pipeline for Parkinson’s Disease, Global, Mean Number of Clinical Trials Per Pipeline Drug, 2006–2012 64
Figure 21: Parkinson’s Disease Market, Global, Efficacy Heat Map for Pipeline Products, 2012–2019 70
Figure 22: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products, 2012–2019 71
Figure 23: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products, 2012–2019 72
Figure 24: Parkinson’s Disease Market, Global, Annual Sales ($bn), 2012–2019 74
Figure 25: Parkinson’s Disease Market, North America, Treatment Patterns, 2012–2019 76
Figure 26: Parkinson’s Disease Market, North America, Annual Cost of Therapy ($), 2012–2019 77
Figure 27: Parkinson’s Disease Market, North America, Market Size ($m), 2012–2019 78
Figure 28: Parkinson’s Disease Market, Top Five EU Countries, Treatment Patterns, 2012–2019 80
Figure 29: Parkinson’s Disease Market, Top Five EU Countries, Annual Cost of Therapy ($), 2012–2019 81
Figure 30: Parkinson’s Disease Market, Top Five EU Countries, Market Size ($m), 2012–2019 82
Figure 31: Parkinson’s Disease Market, Japan, Treatment Patterns and Annual Cost of Therapy ($), 2012–2019 83
Figure 32: Parkinson’s Disease Market, Japan, Market Size ($m), 2012–2019 84
Figure 33: Parkinson’s Disease Market, Global, Co-Development Deals, 2006–2013 89
Figure 34: Parkinson’s Disease Market, Global, Co-Development Deals, 2006–2013 90
Figure 35: Parkinson’s Disease Market, Global, Licensing Deals, 2006–2013 92
Figure 36: Parkinson’s Disease Market, Global, Licensing Deals, 2006–2013 93
Figure 37: Parkinson’s Disease Market, Global, Breakdown of Licensing Deals in Other Non-dopaminergic Neuromodulatory Targets, 2006–2013 94
Figure 38: GBI Research Market Forecasting Model 127

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3500 View Pricing